These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8996520)

  • 41. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
    Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
    J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer.
    Mencoboni M; Lerza R; Castello G; Arboscello E; Barsotti BP; Cerruti A; Ballarino P; Botta M; Bogliolo G; Pannacciulli I
    Anticancer Res; 1997; 17(4A):2795-8. PubMed ID: 9252717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
    Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
    Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
    Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
    J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Re: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Malayeri R
    J Natl Cancer Inst; 2002 Aug; 94(15):1172; author reply 1172. PubMed ID: 12165643
    [No Abstract]   [Full Text] [Related]  

  • 53. New directions for chemotherapy in non-small-cell lung cancer.
    Green MR
    Chest; 1993 Apr; 103(4 Suppl):370S-372S. PubMed ID: 8096453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
    Gavrilov V; Lavrenkov K; Ariad S; Shany S
    Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vinorelbine: a novel vinca alkaloid.
    Toso C; Lindley C
    Am J Health Syst Pharm; 1995 Jun; 52(12):1287-304; quizz 1340-1. PubMed ID: 7656116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.
    Dean EJ; Ward T; Pinilla C; Houghten R; Welsh K; Makin G; Ranson M; Dive C
    Br J Cancer; 2010 Jan; 102(1):97-103. PubMed ID: 19904270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.
    Gameiro SR; Caballero JA; Hodge JW
    Cancer Biother Radiopharm; 2012 Feb; 27(1):23-35. PubMed ID: 22316209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.